Bronte A. Jamison

465 total citations
5 papers, 327 citations indexed

About

Bronte A. Jamison is a scholar working on Genetics, Hematology and Rheumatology. According to data from OpenAlex, Bronte A. Jamison has authored 5 papers receiving a total of 327 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Genetics, 5 papers in Hematology and 4 papers in Rheumatology. Recurrent topics in Bronte A. Jamison's work include Chronic Myeloid Leukemia Treatments (5 papers), Eosinophilic Disorders and Syndromes (4 papers) and Chronic Lymphocytic Leukemia Research (4 papers). Bronte A. Jamison is often cited by papers focused on Chronic Myeloid Leukemia Treatments (5 papers), Eosinophilic Disorders and Syndromes (4 papers) and Chronic Lymphocytic Leukemia Research (4 papers). Bronte A. Jamison collaborates with scholars based in Australia and United States. Bronte A. Jamison's co-authors include Susan Branford, Timothy P. Hughes, David T Yeung, Alexandra L. Yeoman, Haley Altamura, David M. Ross, Stuart Phillis, John F. Seymour, Wendy T Parker and Jodi Braley and has published in prestigious journals such as Blood and British Journal of Cancer.

In The Last Decade

Bronte A. Jamison

5 papers receiving 324 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Bronte A. Jamison Australia	5	307	262	148	51	41	5	327
Alexandra L. Yeoman Australia	5	310 1.0×	263 1.0×	149 1.0×	51 1.0×	42 1.0×	6	330
Haley Altamura Australia	6	382 1.2×	319 1.2×	178 1.2×	73 1.4×	49 1.2×	8	408
Stuart Phillis Australia	5	258 0.8×	223 0.9×	126 0.9×	65 1.3×	52 1.3×	6	295
María Soledad Undurraga Chile	4	425 1.4×	361 1.4×	212 1.4×	43 0.8×	71 1.7×	9	460
Lucy C. Crossman United States	4	283 0.9×	241 0.9×	169 1.1×	35 0.7×	19 0.5×	6	317
Juan Julio Kassack Ipiña Mexico	4	418 1.4×	366 1.4×	210 1.4×	41 0.8×	81 2.0×	5	471
Arta Dreimane Sweden	9	296 1.0×	246 0.9×	123 0.8×	45 0.9×	74 1.8×	17	347
M. C. Muller Germany	7	288 0.9×	235 0.9×	161 1.1×	43 0.8×	26 0.6×	7	350
Nataliia Glushko Ukraine	2	275 0.9×	217 0.8×	120 0.8×	28 0.5×	77 1.9×	2	327
Charlene So United States	5	257 0.8×	224 0.9×	158 1.1×	20 0.4×	22 0.5×	8	273

Countries citing papers authored by Bronte A. Jamison

Since Specialization

Citations

This map shows the geographic impact of Bronte A. Jamison's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bronte A. Jamison with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bronte A. Jamison more than expected).

Fields of papers citing papers by Bronte A. Jamison

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bronte A. Jamison. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bronte A. Jamison. The network helps show where Bronte A. Jamison may publish in the future.

Co-authorship network of co-authors of Bronte A. Jamison

This figure shows the co-authorship network connecting the top 25 collaborators of Bronte A. Jamison. A scholar is included among the top collaborators of Bronte A. Jamison based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bronte A. Jamison. Bronte A. Jamison is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

5 of 5 papers shown

1.

Parker, Wendy T, David T Yeung, Alexandra L. Yeoman, et al.. (2016). The impact of multiple low-level BCR-ABL1 mutations on response to ponatinib. Blood. 127(15). 1870–1880. 50 indexed citations

2.

Branford, Susan, David T Yeung, Wendy T Parker, et al.. (2014). Prognosis for patients with CML and >10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 decline. Blood. 124(4). 511–518. 136 indexed citations

3.

Parker, Wendy T, Alexandra L. Yeoman, Bronte A. Jamison, et al.. (2013). BCR-ABL1 kinase domain mutations may persist at very low levels for many years and lead to subsequent TKI resistance. British Journal of Cancer. 109(6). 1593–1598. 15 indexed citations

4.

Branford, Susan, David T Yeung, David M. Ross, et al.. (2013). Early molecular response and female sex strongly predict stable undetectable BCR-ABL1, the criteria for imatinib discontinuation in patients with CML. Blood. 121(19). 3818–3824. 121 indexed citations

5.

Branford, Susan, David M. Ross, Haley Altamura, et al.. (2012). Early Molecular Response and Female Sex Strongly Predict Achievement of Stable Undetectable BCR-ABL1, a Criterion for Imatinib Discontinuation in Patients with CML. Blood. 120(21). 165–165. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact